Idiosyncratic Liver Toxicity of Nonsteroidal Antiinflammatory Drugs: Molecular Mechanisms and Pathology

References

• Zimmerman H. J. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. Appleton-Century-Crofts, New York 1978
   Google Scholar
• Park B. K., Pirmohamed M., Kitteringham N. R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 1992; 34: 377
   PubMed Web of Science ®Google Scholar
• Nonsteroidal Antiinflammatory Drugs, J. G. Lombardino. John Wiley & Sons, New York 1985
   Google Scholar
• Anti-Inflammatory and Anti-Rheumatic Drugs, K. D. Rainsford. CRC Press, Boca Raton, FL 1985
   Google Scholar
• Knodel L. C., Roush M. K., Barton T. L. Nonsteroidal anti-inflammatory drugs. Clin. Podiatr. Med. Surg. 1992; 9: 301
   PubMedGoogle Scholar
• DeWitt D. L., Meade E. A., Smith W. L. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal drugs. Am. J. Med. 1993; 95: 40
   PubMedGoogle Scholar
• Vane J. Towards a better aspirin. Nature 1994; 367: 215
   PubMed Web of Science ®Google Scholar
• Hutt A. J., Caldwell J. The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1984; 9: 371
   PubMed Web of Science ®Google Scholar
• Hutt A. J., Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids — a novel route with pharmacological consequences. J. Pharm. Pharmacol. 1983; 35: 693
   PubMed Web of Science ®Google Scholar
• Mayer J. M. Stereoselective metabolism of antiinflammatory 2-arylpropionates. Acta Pharm. Nord. 1990; 2: 197
   PubMedGoogle Scholar
• Yuda Y., Tanaka J., Suzuki K., Igarashi K., Satoh T. Inhibitory effects of non-steroidal antiinflammatory drugs on superoxide generation. Chem. Pharm. Bull Tokyo 1991; 39: 1075
   PubMedGoogle Scholar
• Bell A. L., Adamson H., Kirk F., McCaigue M. D., Rotman H. Diclofenac inhibits monocyte superoxide productionex vivo in rheumatoid arthritis. Rheumatol. Int. 1991; 11: 27
   PubMedGoogle Scholar
• Simon L. S. Toxicity of the nonsteroidal antiinflammatory drugs. Current Opin. Rheumatol. 1991; 3: 341
   PubMedGoogle Scholar
• Murray M. D., Brater D. C. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1993; 33: 434
   Google Scholar
• Whelton A., Hamilton C. W. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J. Clin. Pharmacol. 1991; 31: 588
   PubMed Web of Science ®Google Scholar
• Wechter W. J., Bigornia A. E., Murray E. D., Levine B. H., Young J. W. Rac-Flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality 1993; 5: 492
   PubMed Web of Science ®Google Scholar
• Gay G. R. Another side effect of NSAIDs. JAMA 1990; 264: 2677
   PubMedGoogle Scholar
• Doube A. Hepatitis and non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 1990; 49: 489
   PubMedGoogle Scholar
• O'Brien W. M., Bagby G. F. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J. Rheumatol. 1985; 12: 562
   PubMedGoogle Scholar
• Zimmerman H. J. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin. Liver Dis. 1990; 10: 322
   PubMed Web of Science ®Google Scholar
• Rabinovitz M., VanThiel D. H. Hepatotoxicity of nonsteroidal antiinflammatory drugs. Am. J. Gastroenterol. 1992; 87: 1696
   PubMed Web of Science ®Google Scholar
• Lewis J. H. Hepatic toxicity of nonsteroidal antiinflammatory drugs. Clin. Pharm. 1984; 3: 128
   PubMedGoogle Scholar
• Tolman K. G. Hepatotoxicity of antirheumatic drugs. J. Rheumatol. 1990; 17: 6, Suppl. 22
   Google Scholar
• Gutthann S. P., Rodriguez L. A. G. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4: 496
   PubMedGoogle Scholar
• Jick H., Derby L. E., Rodriguez L. A. G., Jick S. S., Dean A. D. Liver disease associated with diclofenac, naproxen, and piroxicam. Pharmacotherapy 1992; 12: 207
   PubMedGoogle Scholar
• Garcia Rodriguez L. A., Gutthann S. P., Walker A. M., Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. Br. Med. J. 1992; 305: 865
   PubMedGoogle Scholar
• Carson J. L., Strom B. L., Duff A., Gupta A., Das K. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch. Intern. Med. 1993; 153: 1331
   PubMedGoogle Scholar
• Hueper W. E. Cinchophen (Atophan): a critical review. Medicine. 1948; 27: 43
   PubMedGoogle Scholar
• Palmer W. L. Cinchophen — is there a safe method of administration. JAMA 1936; 107: 760
   Google Scholar
• Zimmerman H. J., Maddrey W. C. Toxic and drug-induced hepatitis. Diseases of the Liver, 6th ed, L. Schiff, E. R. Schiff. Lippincott, Philadelphia 1987; 591
   Google Scholar
• Paulus H. E. FDA Arthritis Advisory Committee meeting. Arthritis Rheum. 1982; 25: 1124
   PubMedGoogle Scholar
• Kuzell W. C., Schaffarzick R. W., Naugler W. E. Phenylbutazone, further clinical evaluation. Arch. Intern. Med. 1953; 92: 603
   Google Scholar
• Thompson M., Stephenson P., Percy J. S. Ibufenac in the treatment of arthritis. Annu. Rheumat. Dis. 1964; 23: 397
   PubMed Web of Science ®Google Scholar
• Hart F. D., Boardman P. L. Ibufenac (4-isobutylphenyl acetic acid). Annu. Rheumat. Dis. 1965; 24: 61
   PubMed Web of Science ®Google Scholar
• Prescott L. F. Effects of non-narcotic analgesics on the liver. Drugs 1986; 32: 129, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Benjamin S. B., Ishak K. G., Zimmerman H. J., Grushka A. Phenylbutazone liver injury: a clinical pathologic survey of 23 cases and review of the literature. Hepatology 1981; 1: 255
   PubMed Web of Science ®Google Scholar
• Chagnon J. P., Barge J. Hépatite chronique active à la clométacine et antigène HLA B8. Gastroentérol Clin. Biol. 1983; 7: 556
   PubMedGoogle Scholar
• Strieker B. H. C., Blok A. P., Bronkhorst F. B. Glafenine-associated hepatic injury: analysis of 38 cases and review of the literature. Liver 1986; 6: 63
   PubMedGoogle Scholar
• Iveson T. J., Ryley N. G., Kelly P. M. A., Trowell J. ML, McGee J. O, Chapman R. W. G. Diclofenac associated hepatitis. J. Hepatol 1990; 10: 85
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. Hepatic injury associated with nonsteroidal anti-inflammatory drugs. Nonsteroidal Anti-inflammatory Drugs, A. J. Lewis, D. E. Furst. Marcel Dekker, New York 1994; 171
   Google Scholar
• Banks T., Zimmerman H. J., Harter J., Ishak K. G. Diclofenac-associated hepatic injury analysis of 181 cases. Hepatology, in press
   Google Scholar
• Dunk A. A., Walt R. P., Jenkins W. J., Sherlock S. S. Diclofenac hepatitis. Br. Med. J. 1982; 284: 1605
   PubMed Web of Science ®Google Scholar
• Babany G., Pessayre D., Benhamou J. P. Hépatite au diclofenac. Gastroentérol. Clin. Biol. 1983; 7: 316
   PubMedGoogle Scholar
• Deshayes P., Leloet X., Bercoff E., Fouin-Fortunet H. Diclofenac hepatitis. Nouv. Presse Méd. 1984; 13: 1847
   Google Scholar
• Lascar G., Grippon P., Levy V. G. Hépatite aigue mortelle au cours d'un traitement par le diclofenac (Voltarene). Gastroentérol Clin. Biol. 1984; 8: 881
   PubMedGoogle Scholar
• Breen E. G., McNicholl J., Cosgrove E., McCabe J., Stevens F. M. Fatal hepatitis associated with diclofenac. Gut 1986; 27: 1390
   PubMed Web of Science ®Google Scholar
• Schapira D., Bassan L., Nahir A. M., Scharf Y. Diclofenac-induced hepatotoxicity. Postgraduate Med. J. 1986; 62: 63
   PubMed Web of Science ®Google Scholar
• Helfgott S. M., Sandberg-Cook J., Zakim D., Nestler J. Diclofenac-associated hepatotoxicity. JAMA 1990; 264: 2660
   PubMed Web of Science ®Google Scholar
• Purcell P., Henry D., Melville G. Diclofenac hepatitis. Gut 1991; 32: 1381
   PubMed Web of Science ®Google Scholar
• Ouellette G. S., Slitzky G. S., Gates J. A., Lagarde S., West A. B. Reversible hepatitis associated with diclofenac. J. Clin. Gastroenterol. 1991; 13: 205
   PubMedGoogle Scholar
• Scully L. J., Clarke D., Barr R. J. Diclofenac induced hepatitis — three cases with features of autoimmune chronic active hepatitis. Dig. Dis. Sci. 1993; 38: 744
   PubMed Web of Science ®Google Scholar
• Selz F., Cereda J. M. Hépatite subfulminante mortelle au diclofénac. Rev. Méd. Suisse Romande 1993; 113: 985
   PubMedGoogle Scholar
• Stricker B. H. C., Spoelstra P. Drug-induced Liver Injury. Elsevier, Amsterdam 1985
   Google Scholar
• Cuthbert M. G. Adverse reactions to nonsteroidal antiinflammatory drugs. Curr. Med. Res. Opin. 1974; 2: 12
   Web of Science ®Google Scholar
• Lenoir C., Labayle D., Buffet C. Hépatite au clométacine. Now. Presse Méd. 1978; 7: 3035
   PubMedGoogle Scholar
• Manigand G., Pointud P., Taillandier J., Martin E., Bard N., Benoist J. Hépatite à la clométacine. Nouv. Presse Méd. 1979; 8: 213
   PubMedGoogle Scholar
• Mamou P., Levy V. G. Atteintes hépatiques après clométacine 6 cas dont 2 mortels. Nouv. Presse Méd. 1981; 10: 2719
   PubMedGoogle Scholar
• Hillion D., Filsenheld C., Oberlin P. Pericholiangitie chez un adulte traité par clométacine. Gastroentérol. Clin. Biol. 1983; 7: 1038
   PubMedGoogle Scholar
• Tassou J. J., Bretagne J. F., Marion J. Hépatite à la clométacine. Concours Méd. 1981; 103: 679
   Google Scholar
• Pessayre D., Degros P., Feldman G., Degott C. Chronic active hepatitis and grant multinucleated in adults treated with clometacin. Digestion 1981; 22: 66
   PubMed Web of Science ®Google Scholar
• Parini M., Benevent D., Leroux-Robert C. Insuffisance rénale aigue et Hépatite lors d'un traitement par clométacine. Nouv. Presse Méd. 1982; 11: 2641
   Google Scholar
• Poitrine A., Poynard T., Naveu S. Clometacineinduced hepatitis: a fatal crisis. Gastroentérol. Clin. Biol. 1983; 7: 99
   PubMedGoogle Scholar
• Braillon A., Capron J. P., Quichaud J. Hépatite aigue à la clométacine. Interět du dosage des anticorps anti-noyaux et anti-muscle lisse. Gastroentérol. Clin. Biol. 1983; 7: 318
   PubMedGoogle Scholar
• Caruana A., Andre C., Zafrani E. S., Girardin M. F., Metreau J. M., Dhumeaux D. Serum antibodies against double-stranded DNA in chronic active hepatitis: an index of drug-induced liver disease. Lancet 1983; 1: 776
   PubMedGoogle Scholar
• Meyer C., Chassagnon C. Un nouveau cas mortel de cirrhose d à la clométacine. J. Méd. Lyon 1984; 65: 139
   Google Scholar
• Metreau J. M., Andre C., Zafrani E. S., Girdin S. M., Carvana A., Dhumeaux D. Hépatites chroniques actives associées à des anticorps anti-DNA natif: fréquence de l'étiologie médicamenteuse. Gastroentérol. Clin. Biol. 1984; 8: 833
   PubMedGoogle Scholar
• Anderson R. J. Severe reaction associated with sulindac administration. N. Engl. J. Med. 1979; 300: 735
   PubMed Web of Science ®Google Scholar
• Wolfe P. B. Sulindac and jaundice. Ann. Intern. Med. 1979; 91: 656
   PubMed Web of Science ®Google Scholar
• Smith F. E., Lindberg P. J. Life-threatening hypersensitivity to sulindac. JAMA 1980; 244: 269
   PubMedGoogle Scholar
• Kaul A., Reddy J. C., Fagman E., Smith G. F. Hepatitis associated with use of sulindac in a child. J. Pediatr. 1981; 99: 650
   PubMed Web of Science ®Google Scholar
• McIndoe G. A. J., Menzies K. W., Reddy J. Sulindac (Clinoril) and cholestatic jaundice. N. Z. Med. J. 1981; 94: 430
   PubMedGoogle Scholar
• Dhand A. K., LaBreque D. R., Metzger J. Sulindac (Clinoril) hepatitis. Gastroenterology 1981; 80: 585
   PubMed Web of Science ®Google Scholar
• Whittaker S. J., Amar J. N., Wanless I. R., Heathcote J. Sulindac hepatotoxicity. Gut 1982; 23: 875
   PubMed Web of Science ®Google Scholar
• Giroux Y., Moreau M., Kass T. G. Cholestatic jaundice caused by sulindac. Can. J. Surg. 1982; 25: 334
   PubMed Web of Science ®Google Scholar
• Park G. D., Spector R., Headstream T., Goldberg M. Serious adverse reactions associated with sulindac. Arch. Intern. Med. 1982; 142: 1292
   PubMed Web of Science ®Google Scholar
• Kammerer J., Sabaardeil S., Rumeau J. L., Salson A., El-Hage A. Hépatite au sulindac: une observation avec revue des trois précédents. Gastroenterol. Clin. Biol. 1982; 6: 712
   PubMedGoogle Scholar
• Klein S. M., Muhammad A. K. Hepatitis, toxic epidermal neurolysis and pancreatitis in association with sulindac therapy. J. Rheumatol. 1983; 10: 512
   PubMedGoogle Scholar
• Fagan E. A., Walford N., Hodgson H. J. F. Sulindac hepatotoxicity. Gut 1983; 24: 1199
   PubMedGoogle Scholar
• Wood L. J., Searle J., Mundo F., Powell L. W. Sulindac hepatotoxicity: effects of acute and chronic exposure. Aust. N.Z. J. Med. 1985; 15: 397
   PubMedGoogle Scholar
• Gallanosa A. G. Sulindac hepatotoxicity: a case report and review. Clin. Toxicol. 1985; 23: 205
   Google Scholar
• Neufeld M. Y., Karczyn A. D. Encephalopathy associated with sulindac. Hum. Toxicol. 1986; 5: 55
   PubMedGoogle Scholar
• Levitt L., Pearson R. W. Sulindac-induced Stevens Johnson toxic epidermal neurolysis syndrome. JAMA 1980; 243: 1262
   PubMed Web of Science ®Google Scholar
• Bodin F., Habibi B., Legendre C., Schaeffer-Plumet J., Riallin P., Daris F. L'hépatotoxicité du sulindac: une nouvelle observation. Gastroentérol. Clin. Biol. 1985; 9: 546
   PubMedGoogle Scholar
• Tarazi E. M., Harter J. G., Zimmerman H. J., Ishak K. G., Eaton R. A. Sulindac-associated hepatic injury—analysis of 91 cases reported to the food and drug administration. Gastroenterology 1993; 104: 569
   PubMedGoogle Scholar
• Law J. P., Knight H. Jaundice associated with naproxen. N. Engl. J. Med. 1976; 295: 1201
   PubMed Web of Science ®Google Scholar
• Victorino R. M. M., Silveira J. C. B., Baptista A., De Moura M. C. Jaundice associated with naproxen. Postgrad. Med. J. 1980; 56: 368
   PubMed Web of Science ®Google Scholar
• Andrejak M., Davion T., Gineston J. L., Capron J. P. Cross hepatotoxicity between nonsteroidal anti-inflammatory drugs. Br. Med. J. 1987; 295: 180
   PubMedGoogle Scholar
• Giarelli L., Falcomari G., Delender M. Fulminant hepatitis following naproxen administration. Hum. Pathol. 1986; 17: 1079
   PubMedGoogle Scholar
• Bass B. H. Jaundice associated with naproxen. Lancet 1974; 1: 998
   PubMedGoogle Scholar
• Krogsgaard K., Harcht F., Malchow-Miller A. Liver involvement after treatment with naproxen. Ugesker Laeger 1980; 142: 450
   PubMedGoogle Scholar
• Lagarriga J. Naproxen e icteria. Rev. Sanid. Milit. 1975; 29: 250
   Google Scholar
• Bell H., Raknered N. Fulminating hepatitis after treatment with naproxen and/or disulfiram. Tiddskr. Nortluegefuran 1991; 111: 322
   PubMedGoogle Scholar
• Johnson A. G., Day R. O. The problems and pitfalls of NSAID therapy in the elderly. Drugs Aging. 1991; 1: 130
   PubMedGoogle Scholar
• Nash J. F., Carmichael R. H., Ridolfo A. S., Spradin C. T. Pharmacokinetics studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetics metabolic studies. J. Rheumatol. (Suppl.) 1980; 7: 12
   Google Scholar
• Hamdy R. C., Murnang B., Pereran, Hlafsak R. L., Weber J. P. The pharmacokinetics of benoxaprofen in elderly subjects. Eur. J. Rheumatol. Inflamm. 1982; 5: 69
   PubMedGoogle Scholar
• Taggart H. M., Alderdice J. M. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br. Med. J. 1982; 284: 1372
   PubMed Web of Science ®Google Scholar
• Goudie B. M., Birnie G. F., Wathinson G., Masween R. N., Kissen L. H., Cunningham N. E. Jaundice associated with the use of benoxaprofen. Lancet. 1982; 1: 959
   PubMed Web of Science ®Google Scholar
• Prescott L. P., Leslie P. J., Padfield P. Side effects of benoxaprofen. Br. Med. J. 1982; 284: 1783
   Google Scholar
• Firth H., Wilcock G. K., Esiri M., Wilde C. E., Marx J. F. Side effects of benoxaprofen. Br. Med. J. 1982; 284: 1784
   Google Scholar
• Fisher B. M., McArthur J. D. Side effects of benoxaprofen. Br. Med. J. 1982; 284: 1783
   Google Scholar
• Duthie A. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br. Med. J. 1982; 285: 62
   PubMedGoogle Scholar
• Diffey B., Hindson C. Side effects of benoxaprofen. Br. Med. J. 1982; 284: 1630
   PubMedGoogle Scholar
• Fouin-Fortunet H., Lerebours E., Bernet J., Hemet J., Colin R. Hépatite au pirprofène. Annu. Gastroenterol. Hepatol. 1986; 22: 23
   PubMedGoogle Scholar
• Danan G., Trunet P., Bernuau J., Degott C., Babany G., Pessayre D., Ruoff B., Benhamou J. P. Pirprofen-induced fulminant hepatitis. Gastroenterology 1985; 89: 210
   PubMed Web of Science ®Google Scholar
• Castot A., Netter P., Arnaudo J. P., Andrieu J., Vicari F., Ponge B., Wilhelm J. M., Danan G., Trechot P., Felon J. H. Hépatites au pirprofène d'évolution favorable. Thérapie 1984; 39: 297
   PubMedGoogle Scholar
• De Herder W. W., Schröder P., Purnode A., Van Vliet A. C., Strieker B. H. Pirprofen-associated hepatic injury. J. Hepatol. 1987; 4: 127
   PubMedGoogle Scholar
• Reid R. T. Pirprofen and aspirin in rheumatoid arthritis: a double blind comparison study. J. Clin. Pharmacol. 1980; 20: 145
   PubMedGoogle Scholar
• Saykaly R. J., Love D. W., Simon J. A. Comparative efficacy of pirprofen and aspirin in rheumatoid arthritis. J. Clin. Pharmacol. 1979; 19: 56
   PubMedGoogle Scholar
• Singleton C. M., Wild J. H. A double-blind comparison of aspirin and pirprofen in the treatment of rheumatoid arthritis. J. Rheumatol. 1980; 7: 865
   PubMedGoogle Scholar
• Geneve J., Hayat-Bonan B., Labbe G., Degott C., Lettéron C., Fréneaux E., LeDinh T., Larrey D., Pessayre D. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal antiinflammatory drug. J. Pharmacol Exp. Ther. 1987; 242: 1133
   PubMed Web of Science ®Google Scholar
• Ishak K. G., Kirchner J. P., Dhar J. K. Granuloma and cholestatic hepatocellular injury associated with phenylbutazone. Report of two cases. Am. J. Dig. Dis. 1977; 22: 611
   PubMedGoogle Scholar
• Goldstein C. Sarcoid reaction associated with phenylbutazone hypersensitivity. Ann. Intern. Med. 1963; 59: 97
   PubMedGoogle Scholar
• Fowler P. D., Woolf D., Alexander S. Phenylbutazone and hepatitis. Rheum. Rehabil. 1975; 14: 71
   PubMedGoogle Scholar
• Carlisle R. H., Penny C., Prescott C. W., Davidson H. Toxic effects of phenylbutazone on the cat. Br. Vet. J. 1968; 124: 560
   PubMedGoogle Scholar
• Zicha M. The protective effect of L-ornithine-L-aspartate on the liver in rats with drug-induced liver damage. Z. Gastroenterol 1968; 6: 423
   Google Scholar
• Klinger W., Elger J., Franke H., Riencke C., Traeger A., Volkann H., Wahtenberg T., Ankerman H. Untersuchungen zum Mechanismus der Enzyminduktion. XV. Induktionsmuster und submikroskopische Veränderungen in der Leber nach Applikation von Phenylbutazone bei unterschiedlich alten Ratten. Acta Biol. Med. Germ. 1970; 24: 263
   PubMedGoogle Scholar
• Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292
   PubMed Web of Science ®Google Scholar
• Hartmann H., Fischer G., Janning G. Prolonged cholestatic jaundice and leukopenia associated with piroxicam. Z. Gastroenterol. 1984; 22: 343
   PubMedGoogle Scholar
• Lee S. M., O'Brien C. J., Williams R., Whitker S., Gould S. R. Subacute hepatic necrosis induced by piroxicam. Br. Med. J. 1986; 30: 540
   Google Scholar
• Zarski J. P., Aubert H., Dentant L., Rachail M. Hepatitis due to non-steroidal antiinflammatory agents: a new involved molecule, piroxicam (Feldene). Gastroentérol. Clin. Biol. 1984; 12: 980
   Google Scholar
• Planas R., Leon R. D., Quer J. C., Barranco C., Bruguera M., Gassull M. A. Fatal submassive necrosis of the liver associated with piroxicam. Am. J. Gastroenterol. 1990; 5: 468
   Google Scholar
• Bismuth H., Samuel D., Gugenheim J., Castaing D., Bernuau J., Rueff B., Benhamou J. P. Emergency liver transplantation for fulminant hepatitis. Ann. Intern. Med. 1987; 107: 337
   PubMed Web of Science ®Google Scholar
• Caballeria E., Masso R. M., Arago I. V., Sanchis A. Piroxicam hepatotoxicity. Am. J. Gastroenterol. 1990; 85: 898
   PubMedGoogle Scholar
• Hepps K. S., Maliha G. M., Estrada R., Goodgame R. W. Severe cholestatic jaundice associated with piroxicam. Gastroenterology 1991; 101: 1737
   PubMedGoogle Scholar
• Paterson D., Kerlin P., Walker N., Lynch S., Strong R. Piroxicam-induced submassive necrosis of the liver. Gut 1992; 33: 1436
   PubMedGoogle Scholar
• Godfrey K. E., Swain M. C. Fenclofenac. Anti-Inflammatory and Anti-Rheumatic Drugs, K. D. Rainsford. CRC Press, Boca Raton, FL 1985; 105
   Google Scholar
• Fowler P. D. Voltarol: diclofenac sodium. Clin. Rheumat. Dis. 1979; 5: 427
   Google Scholar
• Zimmerman H. J. Effects of aspirin and acetaminophen on the liver. Arch. Intern. Med. 1981; 141: 33
   Google Scholar
• Pohl L. R., Satoh H., Christ D. D., Kenna J. G. Immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. 1988; 23: 367
   Google Scholar
• Pohl L. R. Drug-induced allergic hepatitis. Semin. Liver Dis. 1990; 10: 305
   PubMed Web of Science ®Google Scholar
• Pessayre D. Physiopathologie des hépatopathies médicamenteuses. Gastroentérol. Clin. Biol. 1993; 17: H3
   PubMedGoogle Scholar
• Zhao J., Leemann T., Dayer P. In vitro oxidation of oxicam NSAIDs by a human liver cyto-chrome-P450. Life Sci. 1992; 51: 575
   PubMed Web of Science ®Google Scholar
• Leemann T., Transon C., Dayer P. Cytochrome-P450TB (CYP2C) — a major monooxygenase catalyzing diclofenac 4α-hydroxylation in human liver. Life Sci. 1993; 52: 29
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A., Boelsterli U. A. Diclofenac covalent protein binding is dependent on acylglucuronide formation and is inversely related to acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 1993; 120: 155
   PubMed Web of Science ®Google Scholar
• Leemann T. D., Transon C., Bonnabry P., Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exptl. Clin. Res. 1993; 19: 189
   PubMedGoogle Scholar
• Brune K. Is there a rational basis for the different spectra of adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Drugs 1990; 40: 12, Suppl. 5
   PubMedGoogle Scholar
• Mitchell M. C., Lietman P. S. Evidence for the role of reactive metabolites in hepatotoxicity of benoxaprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs). Hepatology 1983; 3: 808
   Google Scholar
• Brune K., Lanz R. Pharmacokinetics of nonsteroidal anti-inflammatory drugs. Handbook of Inflammation, Vol. 5, The Pharmacology of Inflammation, I. L. Bonta, M. A. Bray, M. J. Parnham. Elsevier, Amsterdam 1985; 413
   Google Scholar
• Brune K., Beck W. S. Towards safer nonsteroidal anti-inflammatory drugs. Agents Actions 1991; 32: 13, Suppl.
   PubMedGoogle Scholar
• Magdalou J., Chajes V., Lafaurie C., Siest G. Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab. Disp. 1990; 18: 692
   PubMed Web of Science ®Google Scholar
• Jordan B. J., Ranee M. J. Taurine conjugation of fenclofenac in the dog. J. Pharm. Pharmacol. 1974; 26: 359
   PubMed Web of Science ®Google Scholar
• Stierlin H., Faigle J. W., Sallmann A., Küng W., Richter W. J., Kriemler H. P., Alt K. O., Winkler T. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. Xenobiotica 1979; 9: 601
   PubMed Web of Science ®Google Scholar
• Sengupta C., Afèche P., Meyer-Brunot H. G., Rensing U. Diclofenac sodium. Anti-inflammatory and Anti-Rheumatic Drugs, K. D. Rainsford. CRC Press, Boca Raton, FL 1985; 49
   Google Scholar
• Watt J. A., King A. R., Dickinson R. G. Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. Xenobiotica 1991; 21: 403
   PubMed Web of Science ®Google Scholar
• Jansen P. L. M., Mulder G. J., Burchell B., Bock K. W. New developments in glucuronidation research: report of a workshop on “glucuronidation, its role in health and disease”. Hepatology 1992; 15: 532
   PubMed Web of Science ®Google Scholar
• Miners J. O., Mackenzie P. I. Drug glucuronidation in humans. Pharmacol. Titer. 1991; 51: 347
   PubMed Web of Science ®Google Scholar
• Jin C., Miners J. O., Lilly white K. J., Mackenzie P. I. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate—glucuronosyl transferase glucuronidating carboxylic acid-containing drugs. J. Pharmacol. Exp. Ther. 1993; 264: 475
   PubMed Web of Science ®Google Scholar
• Mulder G. J. Glucuronidation and its role in regulation of biological activity of drugs. Annu. Rev. Pharmacol. Toxicol. 1992; 32: 25
   PubMed Web of Science ®Google Scholar
• Kroemer H. K., Klotz U. Glucuronidation of drugs — a reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin. Pharmacokinet. 1992; 23: 292
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H., Benet L. Z. Acyl glucuronides revisited — is the glucuronidation process a toxification as well as a detoxification mechanism. Drug Metab. Rev. 1992; 24: 5
   PubMed Web of Science ®Google Scholar
• Dickinson R. G. Acyl glucuronide conjugates: reactive metabolites of non-steroidal anti-inflammatory drugs. Proc. West. Pharmacol. Soc. 1993; 36: 157
   PubMedGoogle Scholar
• Faed E. M. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 1984; 15: 1213
   PubMed Web of Science ®Google Scholar
• Van Breemen R. B., Fenselau C. Acylation of albumin by 1-O-acyl glucuronides. Drug Metab. Disp. 1985; 13: 318
   PubMed Web of Science ®Google Scholar
• Lapicque F., Muller N., Payan E., Dubois N., Netter P. Protein binding and stereoselectivity of nonsteroidal antiinflammatory drugs. Clin. Pharmacokinet. 1993; 25: 115
   PubMed Web of Science ®Google Scholar
• Ojingwa J. C., Spahn-Langguth H., Benet L. Z. Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J. Pharmacokinet. Biopharmaceut. 1994; 22: 19
   PubMedGoogle Scholar
• Wells D. S., Janssen F. W., Ruelius H. W. Interactions between oxaprozin glucuronide and human serum albumin. Xenobiotica 1987; 17: 1437
   PubMed Web of Science ®Google Scholar
• Small R. E. Diclofenac sodium. Clin. Pharmacy. 1989; 8: 545
   PubMedGoogle Scholar
• Maruyama T., Lin C. C., Yamasaki K., Miyoshi T., Imai T., Yamasaki M., Otagiri M. Binding of suprofen to human serum albumin. Role of the suprofen carboxyl group. Biochem. Pharmacol. 1993; 45: 1017
   PubMed Web of Science ®Google Scholar
• Hayball P. J., Nation R. L., Bochner F. Stereoselective interactions of ketoprofen glucuronides with human plasma protein and serum albumin. Biochem. Pharmacol. 1992; 44: 291
   PubMedGoogle Scholar
• Verbeeck R. K., Blackburn J. L., Loewen G. R. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1983; 8: 297
   PubMed Web of Science ®Google Scholar
• Ruelius H. W., Kirkman S. K., Young E. M., Janssen F. W. Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin. Adv. Exp. Med. Biol. 1986; 197: 431
   PubMedGoogle Scholar
• Benet L. Z., Spahn-Langguth H., Iwakawa S., Volland C., Mizuma T., Mayer S., Mutschler E., Lin E. T. Predictability of the covalent binding of acidic drugs in man. Life Sci. 1993; 53: PL141
   PubMed Web of Science ®Google Scholar
• Smith P. C., McDonagh A. F., Benet L. Z. Irreversible binding of zomepirac to plasma proteinin vitro and. in vivo, J. Clin. Invest. 1986; 77: 934
   PubMed Web of Science ®Google Scholar
• Smith P. C., Benet L. Z., McDonagh A. F. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metah. Disp. 1990; 18: 639
   PubMed Web of Science ®Google Scholar
• Smith P. C., Liu J. H. Covalent binding of suprofen acyl glucuronide to albumin. in vitro, Xenobiotica 1993; 23: 337
   PubMed Web of Science ®Google Scholar
• Ding A., Ojingwa J. C., McDonagh A. F., Burlingame A. L., Benet L. Z. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 3797
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A., Boelsterli U. A. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins: retention of the glucuronic acid moiety in the adduct. Drug Metab. Disp. 1994; 22: 956
   PubMed Web of Science ®Google Scholar
• Dickinson R. G., King A. R. Studies on the reactivity of acyl glucuronides. II. Interaction of diflunisal acyl glucuronide and its isomers with human serum albumin. in vitro, Biochem. Pharmacol. 1991; 42: 2301
   PubMed Web of Science ®Google Scholar
• Dubois N., Lapicque F., Maurice M. H., Pritchard M., Fournelgigleux S., Magdalou J., Abiteboul M., Siest G., Netter P. In vitro irreversible binding of ketoprofen glucuronide to plasma proteins. Drug Metab. Disp. 1993; 21: 617
   PubMed Web of Science ®Google Scholar
• Iwakawa S., Spahn H., Benet L. Z., Lin E. T. Carprofen acyl glucuronides: stereoselective degradation and interaction with human serum albumin. Pharm. Res. 1988; 5: S-214, Suppl.
   PubMedGoogle Scholar
• Smith P. C., Song W. Q, Rodriguez R. J. Covalent binding of etodolac acyl glucuronide to albumin. in vitro. Drug Metab. Disp. 1992; 20: 962
   PubMed Web of Science ®Google Scholar
• Hyneck M. L., Smith P. C., Munafo A., McDonagh A. F., Benet L. Z. Disposition and irreversible plasma protein binding of tolmetin in humans. Clin. Pharmacol. Ther. 1988; 44: 107
   PubMed Web of Science ®Google Scholar
• Zia-Amirrhosseini P., Ojingwa J. C., Spahn-Langguth H., McDonagh A. F., Benet L. Z. Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing. Clin. Pharmacol. Ther. 1994; 55: 21
   PubMedGoogle Scholar
• King A. R., Dickinson R. G. Studies on the reactivity of acyl glucuronides. IV. Covalent binding of diflunisal to tissues of the rat. Biochem. Pharmacol. 1993; 45: 1043
   PubMed Web of Science ®Google Scholar
• Munafo A., Hyneck M. L., Benet L. Z. Pharmacokinetics and irreversible binding of tolmetin and its glucuronic acid esters in the elderly. Pharmacology 1993; 47: 309
   PubMedGoogle Scholar
• McKinnon G. E., Dickinson R. G. Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. Res. Comm. Chem. Pathol. Pharmacol. 1989; 66: 339
   PubMedGoogle Scholar
• Dohlman J. G., Pillion D. J., Rokeach L. A., Ramprasad M. P. Identification of macrophage cell-surface binding sites for cationized bovine serum albumin. Biochem. Biophys. Res. Comm. 1991; 181: 787
   PubMed Web of Science ®Google Scholar
• Williams A. M., Worrall S., Dejersey J., Dickinson R. G. Studies on the reactivity of acyl glucuronides. VIII. Generation of an antiserum for the detection of diflunisal-modified proteins in diflunisal-dosed rats. Biochem. Pharmacol., in press
   Google Scholar
• Dickinson R. G., King A. R. Studies on the reactivity of acyl glucuronides. V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and beta-glucuronidase. Biochem. Pharmacol. 1993; 46: 1175
   PubMed Web of Science ®Google Scholar
• Noort D., Coughtrie M. W. H., Burchell B., Van der Marel G. A., Van Boom J. H., Mulder G. J. Inhibition of UDP glucuronosyltransferase activity by possible transition state analogues in rat liver microsomes. Eur. J. Biochem. 1990; 188: 309
   PubMedGoogle Scholar
• Spahn H., Näthke I., Mohri K., Zia-Amirrhosseini P., Benet L. Z. Preliminary characterization of proteins to which benoxaprofen glucuronide binds irreversibly. Pharm. Res. 1990; 7: S-257, Suppl
   Google Scholar
• Pumford N. R., Davila J. C., Myers T. G., Pohl L. R. Immunochemical detection of a major diclofenac-protein adduct in mouse liver: possible role in hepatotoxicity. Toxicologist 1992; 12: 253
   Google Scholar
• Pumford N. R., Myers T. G., Davila J. C., Highet R. J., Pohl L. R. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 1993; 6: 147
   PubMed Web of Science ®Google Scholar
• Hargus S. J., Amouzedeh H. R., Pumford N. R., Myers T. G., McCoy S. C., Pohl L. R. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 1994; 7: 575
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A., Boelsterli U. A. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac. Radiochemical and immunochemical analysis. Mol. Pharmacol. 1994; 45: 237
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A., Boelsterli U. A. Liver, lung, and spleen as target tissues for protein adduct formation associated with metabolism of the nonsteroidal antiinflammatory drug diclofenac. Toxicologist 1994; 14: 425
   Google Scholar
• Myers T. G., Pumford N. R., Davila J. C., Pohl L. R. Covalent binding of diclofenac to plasma membrane proteins of the bile canaliculi in the mouse. Toxicologist 1992; 12: 253
   Google Scholar
• Loeper J., Descatoire V., Amouyal G., Lettéron P., Larrey D., Pessayre D. Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man. Hepatology 1989; 9: 675
   PubMed Web of Science ®Google Scholar
• Satoh H., Gillette J. R., Davies H. W., Schulick R. D., Pohl L. R. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol. Pharmacol. 1985; 28: 468
   PubMed Web of Science ®Google Scholar
• Coombs R. R. A., Gell P. G. H. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Clinical Aspects of Immunology, R. R. A. Coombs, P. G. H. Gell. F. A. Davis, New York 1968; 575
   Google Scholar
• De Week A. L. Immunopafhological mechanisms and clinical aspects of allergic reactions to drugs. Allergic Reactions to Drugs, A. L. De Week, H. Bungaard. Springer-Verlag, Berlin 1983; 75
   Google Scholar
• Franco A., Barnaba V., Natali P., Balsano C., Musca A., Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8: 449
   PubMed Web of Science ®Google Scholar
• So S. K. S., Platt J. L., Ascher N. L., Simmons R. L. Purified hepatocytes can stimulate allospecific cytoloytic T lymphocytes in a mixed lymphocyte-hepatocyte culture. Transplant Proc. 1987; 19: 251
   PubMedGoogle Scholar
• Harris H. W., Gill T. J. Expression of class I transplantation antigens. Transplantation 1986; 42: 109
   PubMedGoogle Scholar
• Chedid A., Mendenhall C. L., Moritz T. E., French S. W., Chen T. S., Morgan T. R., Roselle G. A., Nemchausky B. A., Tamburro C. H., Schiff E. R., McClain C. J., Marsano L. S., Allen J. I., Samanta A., Weesner R. E., Henderson W. G. Cell-mediated hepatic injury in alcoholic liver disease. Gastroenterology 1993; 105: 254
   PubMed Web of Science ®Google Scholar
• Calmus Y., Arvieux C., Gane P., Boucher E., Nordlinger B., Rouger P., Poupon R. Cholestasis induces major histocompatibility complex class-I expression in hepatocytes. Gastroenterology 1992; 102: 1371
   PubMedGoogle Scholar
• Arvieux C., Calmus Y., Gane P., Legendre C., Mariani P., Delelo R., Poupon R., Nordlinger B. Immunogenicity of rat hepatocytesin vivo — effect of cholestasis-induced changes in major histocompatibility complex expression. J. Hepatol. 1993; 18: 335
   PubMedGoogle Scholar
• Lobo-Yeo A., Senaldi G., Portmann B., Mowat A. P., Mieli-Vergani G., Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocyes: a study in children with liver disease. Hepatology 1990; 12: 224
   PubMed Web of Science ®Google Scholar
• Van den Oord J., De Vos R., Desmet V. J. HLA expression in liver disease. Progress in Liver Diseases, H. Popper, F. Schaffner. W.B. Saunders, Philadelphia 1990; Vol. 9: 73
   Google Scholar
• Volpes R., Vandenoord J. J., Desmet V. J. Can hepatocytes serve as activated immunomodulating cells in the immune response. J. Hepatol. 1992; 16: 228
   PubMedGoogle Scholar
• Homberg J. C., Abuaf N., Helmy-Khalil S., Biour M., Poupon R., Islam S., Darnis F., Levy V. G., Opolon P., Beaugrand M., Toulet J., Danan G., Benhamou J.-P. Drug-induced hepatitis associated with anticytoplasmatic organelle autoantibodies. Hepatology 1985; 5: 722
   PubMed Web of Science ®Google Scholar
• Macogon N. V., Alexeyeva I. N. Xenogeneic antibodies against hepatocyte plasma membranes suppress bile secretion in rats. Exp. Toxic. Pathol. 1993; 45: 211
   PubMedGoogle Scholar
• Doherty P. C. Cell-mediated cytotoxicity. Cell 1993; 75: 607
   PubMed Web of Science ®Google Scholar
• Kägi D., Ledermann B., Bürki K., Seiler P., Odermatt B., Olsen K. J., Podack E. R., Zinkernagel R. M., Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31
   PubMed Web of Science ®Google Scholar
• Vergani D., Mieli-Vergani G., Alberti A., Neuberger J., Eddleston A., Davis M., Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 1980; 303: 66
   PubMed Web of Science ®Google Scholar
• Neuberger J., Kenna J. G., Nouri A. K., Williams R. Antibody mediated hepatocyte injury in methyl dopa induced hepatotoxicity. Gut 1985; 26: 1233
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A., Boelsterli U. A. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngenic hepatocytes exposed to diclofenac. Hepatology 1995; 22, in Press
   PubMedGoogle Scholar
• Sidrouphis L., Beaugrand M., Malledant Y., Brissot P., Guguen-Guillouzo C., Guillouzo A. Use of adult human hepatocytes in primary culture for the study of clometacin-induced immunoallergic hepatitis. Toxic, in Vitro. 1991; 5: 529
   PubMedGoogle Scholar
• Pariente E. A., Hamoud A., Goldfain D., Latrive J. P., Gislon J., Cassan P., Morin T., Staub J.-L., Ramain J.-P., Bertrand J.-L., Denis J., Lafon J., Labayle D., Druart F., Bianchi A., Kammerer J. Hépatites à la clométacine (Dupéran®). Etude rétrospective de 30 cas. Un modèle d'hépatite autoimmune médicamenteuse. Gastroentérol. Clin. Biol. 1989; 13: 769
   PubMed Web of Science ®Google Scholar
• Toh B. H. Anti-cytosceletal autoantibodies: diagnostic significance for liver diseases, infections and systemic autoimmune diseases. Autoimmunity 1991; 11: 119
   PubMed Web of Science ®Google Scholar
• Hillon P., Bedenne L., Piard F., Regis P. Clometacine-induced hepatitis. Digest. Dis. Sci. 1988; 33: 1045
   PubMedGoogle Scholar
• Meyer zum Büschenfelde K.-H., Lohse A. W., Manns M., Poralla T. Autoimmunity and liver disease. Hepatology 1990; 12: 354
   PubMedGoogle Scholar
• Czaja A. J., Carpenter H. A., Santrach P. J., Moore S. B. Genetic predisposition for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816
   PubMed Web of Science ®Google Scholar
• Nepom G. T., Erlich H. MHC class II molecules and autoimmunity. Annu. Rev. Immunol. 1991; 9: 493
   PubMed Web of Science ®Google Scholar
• Raz E., Ben-Bassat H., Davidi T., Shlomai Z., Eilat D. Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur. J. Immunol. 1993; 23: 383
   PubMed Web of Science ®Google Scholar
• Naparstek Y., Plotz P. H. The role of autoantibodies in autoimmune disease. Annu. Rev. Immunol. 1993; 11: 79
   PubMed Web of Science ®Google Scholar
• Islam S., Mekhloufi F., Paul J. M., Islam M., Johanet C., Legendre C., Degott C., Abuaf N., Homberg J. C. Characteristics of clometacin-induced hepatitis with special reference to the presence of anti-actin cable antibodies. Autoimmunity 1989; 2: 213
   PubMed Web of Science ®Google Scholar
• Chatfield D. H., Green J. Disposition and metabolism of benoxaprofen in laboratory animals and man. Xenobiotica 1978; 8: 133
   PubMed Web of Science ®Google Scholar
• Sorensen E. M. B., Acosta D. Relative toxicities of several nonsteroidal antiinflammatory compounds in primary cultures of rat hepatocytes. J. Toxicol. Environ. Health. 1985; 16: 425
   PubMed Web of Science ®Google Scholar
• Castell J. V., Larrauri A., Gomez-Lechon M. J. A study of the relative hepatotoxicityin vitro of the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and butibufen. Xenobiotica 1988; 18: 737
   PubMed Web of Science ®Google Scholar
• Knights K. M., Cassidy M. R., Drew R. Benoxaprofen-induced toxicity in isolated rat hepatocytes. Toxicology 1986; 40: 327
   PubMedGoogle Scholar
• Jurina-Romet M., Crawford K., Huang H. S. Comparative cytotoxicity of non-steroidal antiinflammatory drugs in primary cultures of rat hepatocytes. Toxic, in Vitro 1994; 8: 55
   PubMedGoogle Scholar
• Schmitz G., Stauffert I., Sippel H., Lepper H., Estler C. J. Toxicity of diclofenac to isolated hepatocytes. J. Hepatol. 1992; 14: 408
   PubMedGoogle Scholar
• Matsubara T., Touchi A., Masuda Y. Pharmacological studies of a new antiinflammatory drug, benoxaprofen. III. Effect on the hepatic drug-metabolizing enzyme system. Oyo Yakuri 1982; 23: 267
   Google Scholar
• Gasperini R., Leone R., Velo G. P., Fracasso M. E. The inhibition of hepatic microsomal drug metabolism in rats by non-steroidal anti-inflammatory drugs. Pharmacol. Res. 1990; 22: 115, Suppl. 3
   PubMedGoogle Scholar
• Brown L. M., Ford-Hutchinson A. W. The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite. Biochem. Pharmacol. 1982; 31: 195
   PubMed Web of Science ®Google Scholar
• Kemmelmeier F. S., Bracht A. Effects of the nonsteroidal anti-inflammatory drug mefenamic acid on energy metabolism in the perfused rat liver. Biochem. Pharmacol. 1989; 38: 823
   PubMedGoogle Scholar
• Yokoyama H., Horie T., Awazu S. Lipid peroxidation in rat liver microsomes during naproxen metabolism. Biochem. Pharmacol. 1993; 45: 1721
   PubMedGoogle Scholar
• Williams K., Day R., Knihinicki R., Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem. Pharmacol. 1986; 35: 3403
   PubMed Web of Science ®Google Scholar
• Mayer J. M., Roy-de-Vos M., Audergon C., Testa B., Etter J. C. Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids:in vitro studies. Int. J. Tiss. Reac. 1994; 16: 59
   PubMedGoogle Scholar
• Mayer J., Testa B. Stereoselectivity in metabolic reactions of toxication and detoxication. Handbook of Experimental Pharmacology. Pharmacokinetics and Drug Metabolism, L. P. Ballant, P. G. Welling. Springer, Stuttgart 1994, in press
   Google Scholar
• Caldwell J., Marsh M. V. Interrelationships between xenobiotic metabolism and lipid biosynthesis. Biochem. Pharmacol. 1983; 32: 1667
   PubMed Web of Science ®Google Scholar
• Freneaux E., Fromenty B., Berson A., Labbe G., Degott C., Lettéron P., Larrey D., Pessayre D. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J. Pharmacol. Exp. Ther. 1990; 255: 529
   PubMed Web of Science ®Google Scholar
• Pessayre D., Mazel P., Descatoire V., Rogier E., Feldman G., Benhamou J. P. Inhibition of hepatic drug-metabolizing enzymes by arachidonic acid. Xenobiotica 1979; 9: 301
   PubMed Web of Science ®Google Scholar
• Trudell J. R., Gut J., Costa A. K. Leukotrienes in hepatocyte injury. Modulation of Liver Cell Expression, W. Reutter, P. C. Heinrich, H. Popper, D. Keppler, I. M. Arias, L. Landmann. MTP Press, Lancaster 1987; 411
   Google Scholar
• Hagmann W., Kirn A., Keppler D. Role of leukotrienes in acute inflammatory liver disease. Modulation of Liver Cell Expression, W. Reutter, P. C. Heinrich, H. Popper, D. Keppler, I. M. Arias, L. Landmann. MTP Press, Lancaster 1987; 423
   Google Scholar
• Garcia Rodriguez L. A., Williams R., Derby L. E., Dean A. D., Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch. Intern. Med. 1994; 154: 311
   PubMedGoogle Scholar
• Pacifici G. M., Viani A., Franchi M., Santerini S., Temellini A. Conjugation pathways in liver disease. Br. J. Clin. Pharmacol. 1990; 30: 427
   PubMedGoogle Scholar
• Verbeeck R. K., Dickinson R. G., Pond S. M. Biliary excretion of diflunisal conjugates in patients with T-tube drainage. Eur. J. Clin. Pharmacol. 1988; 34: 423
   PubMed Web of Science ®Google Scholar
• Ramadori G., Moebius U., Dienes H.-P., Meuer S., Meyer zum Büschenfelde K.-H. Lymphocytes from hepatic inflammatory infiltrate kill rat hepatocytes in primary culture. Virchows Archiv. B Cell Pathol. 1990; 59: 263
   Google Scholar
• Tsutsui H., Terano Y., Sakagami C., Hasegawa I., Mizoguchi Y., Morisawa S. Drug-specific T-cells derived from patients with drug-induced allergic hepatitis. J. Immunol. 1992; 149: 706
   PubMed Web of Science ®Google Scholar
• Gut J., Christen U., Huwyler J., Bürgin M., Kenna J. G. Molecular mimicry of trifluoroacety lated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur. J. Biochem. 1992; 210: 569
   PubMedGoogle Scholar
• Christen U., Bürgin M., Gut J. Halothane metabolism — immunochemical evidence for molecular mimicry of trifluoroacetylated liver protein adducts by constitutive polypeptides. Mol. Pharmacol. 1991; 40: 390
   PubMed Web of Science ®Google Scholar
• Christen U., Jeno P., Gut J. Halothane metabolism — the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts. Biochemistry 1993; 32: 1492
   PubMedGoogle Scholar
• Wiseman E. H. Pharmacologic studies with a new class of nonsteroidal anti-inflammatory agents — the oxicams — with special reference to piroxicam (Feldene®). Am. J. Med. 1982; 72: 2
   Google Scholar